DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics
by Zacks Equity Research
Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Here's Why You Should Hold McKesson (MCK) in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) fiscal second-quarter performance is likely to benefit from strong growth in the United States and the International front
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford
by Zacks Equity Research
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
UnitedHealth (UNH) Faces Investigation Following Cyberattack
by Zacks Equity Research
A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Revvity's (RVTY) New Launch to Boost Research Productivity
by Zacks Equity Research
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
by Zacks Equity Research
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
by Zacks Equity Research
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery
by Zacks Equity Research
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
Here's Why You Should Retain HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
Cencora (COR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).